OKYO Pharma Limited
NASDAQ:OKYOBiotechnology
+$0.01 today
- Market cap
- $57.73M
- Beta
- 0.02
- P/E (TTM)
- -12.8
- EPS (TTM)
- -$0.12
Volume 0.24M
Average 0.07M
OKYO Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
OKYO Pharma LimitedNASDAQ: OKYO
Depreciation & Amortization · Q2 FY2026 · quarter ended Sep 2025
Depreciation & amortization declines year over year
Q2 FY2026 depreciation & amortization of $885 fell 30.5% year over year. Over 3 fiscal years it compounded at +3.2% a year.
Context
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 2.56K USD
- Year-over-year change
- -33.7%
- 4-year CAGR
- -33.5%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-03-31 | 2.56K | -33.7% |
| FY2024 | 2024-03-31 | 3.87K | +1.8% |
| FY2023 | 2023-03-31 | 3.8K | +62.9% |
| FY2022 | 2022-03-31 | 2.33K | -82.2% |
| FY2021 | 2021-03-31 | 13.11K | — |
Depreciation & Amortization vs competitors
How OKYO compares with its peers on the latest reported figures
- OKYO's FY2025 depreciation & amortization of $2.56K is the 9th highest of the 10 companies compared; the peer median is $398.22K.
- Its year-over-year change of -33.7% is the 7th highest of 10, against a peer median of -14.7%.
- Over three fiscal years its annual growth of +3.2% compares with a peer median of -15.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $7.09M | -5.1% | -15.4% | 4.5% | |
| LTM Mar 2026 | $1.51M | -26.6% | -22.8% | — | |
| LTM Mar 2026 | $1.45M | -11.2% | +13.6% | 1079.1% | |
| LTM Mar 2026 | $628K | -48.8% | -19.7% | — | |
| LTM Mar 2026 | $398.22K | +164.2% | +454.8% | — | |
| FY2025 | $234K | +88.7% | +55.1% | — | |
| LTM Mar 2026 | $23.33K | -14.7% | +0.0% | 0.3% | |
WHWKWhitehawk Therapeutics Inc | LTM Mar 2026 | $22K | -88.5% | -20.8% | — |
| FY2025 | $2.56K | -33.7% | +3.2% | — | |
| LTM Mar 2026 | $0 | -100.0% | -42.1% | 0.0% | |
| Peer median (excluding OKYO) | $398.22K | -14.7% | -15.4% | 2.4% | |
Competitors are the stored peer set for OKYO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Mar 2021 | FY2022 Mar 2022 | FY2023 Mar 2023 | FY2024 Mar 2024 | FY2025 Mar 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 13.09K | 2.42K | 3.8K | 3.87K | 2.56K |
| Gross Profit | (13.09K) | (2.42K) | (3.8K) | (3.87K) | (2.56K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 348.35K | 1.61M | 6.34M | 8.24M | 2.25M |
| Selling, General & Admin | 2.97M | 4.93M | 6.75M | 7.45M | 4.93M |
| Operating Expenses | 3.37M | 6.22M | 6.34M | 15.69M | 7.19M |
| Depreciation & Amortization | 13.11K | 2.33K | 3.8K | 3.87K | 2.56K |
| EBITDA | (3.35M) | (6.22M) | (13.18M) | (15.75M) | (7.08M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (4.13M) | (6.23M) | (13.09M) | (15.69M) | (7.19M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 0 | 0 | 5.47K |
| Interest Expense | 1.12K | 0 | 96.69K | 1.05M | 883.65K |
| Other Income / Expenses | 754.85K | 13.58K | (196.62K) | (1.11M) | (781.2K) |
| Income Before Tax | (3.38M) | (6.22M) | (13.28M) | (16.8M) | (7.97M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | (24.99K) | (787K) | (12.2K) | 22.42K | (3.26M) |
| Net Income | (3.35M) | (5.43M) | (13.27M) | (16.83M) | (4.71M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.32) | (0.36) | (0.60) | (0.00) | (0.12) |
| EPS (Diluted) | (0.32) | (0.36) | (0.60) | (0.00) | (0.12) |
| Weighted Avg Shares | 10.35M | 15.06M | 22.26M | 29.34M | 39.49M |
| Weighted Avg Shares (Diluted) | 10.35M | 15.06M | 22.26M | 29.34M | 39.49M |
OKYO Pharma Limited
NASDAQ:OKYO
Intrinsic Alpha fair value
Locked
Current Price
$1.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.